Leukotriene A 4 (LTA 4 ) hydrolase catalyzes a rate-limiting final biosynthetic step of leukotriene B 4 (LTB 4 ), a potent lipid chemotatic agent and proinflammatory mediator. LTB 4 has been implicated in the pathogenesis of various acute and chronic inflammatory diseases, and thus LTA 4 hydrolase is regarded as an attractive therapeutic target for anti-inflammation. To facilitate identification and optimization of LTA 4 hydrolase inhibitors, a specific and efficient assay to quantify LTB 4 is essential. This article describes the development of a novel 384-well homogeneous time-resolved fluorescence assay for LTB 4 (LTB 4 HTRF ® assay) and its application to establish an HTRF-based LTA 4 hydrolase assay for lead optimization. This LTB 4 HTRF assay is based on competitive inhibition and was established by optimizing the reagent concentration, buffer composition, incubation time, and assay miniaturization. The optimized assay is sensitive, selective, and robust, with a Z´ factor of 0.89 and a subnanomolar detection limit for LTB 4 . By coupling this LTB 4 HTRF assay to the LTA 4 hydrolase reaction, an HTRFbased LTA 4 hydrolase assay was established and validated. Using a test set of 16 LTA 4 hydrolase inhibitors, a good correlation was found between the IC 50 values obtained using LTB 4 HTRF with those determined using the LTB 4 enzyme-linked immunoassay (R = 0.84). The HTRF-based LTA 4 hydrolase assay was shown to be an efficient and suitable assay for determining compound potency and library screening to guide the development of potent inhibitors of LTA 4 hydrolase. (Journal of Biomolecular Screening 2007:536-545) 
INTRODUCTION
L EUKOTRIENE A 4 (LTA 4 ) HYDROLASE, a bifunctional zinc metalloenzyme, exhibits both epoxide hydrolase and aminopeptidase activities. 1 Although the enzyme is capable of hydrolyzing certain synthetic dipeptides or tripeptides, no physiological substrate has been identified so far for the aminopeptidase activity. The important physiological function of LTA 4 hydrolase resides in its epoxide hydrolase activity (i.e., the conversion of a chemically unstable epoxide LTA 4 to leukotriene B 4 [LTB 4 ]). LTB 4 is a potent chemoattractant of human neutrophils and a lipid mediator in modulating immune response. 2, 3 LTA4 hydrolase has thus been implicated in the pathogenesis of various acute and chronic inflammatory diseases. Elevation of LTB 4 level has been detected in biological fluids from patients with active multiple sclerosis, 4 scleroderma lung disease, 5 pneumonia, tuberculosis, or cancer. 6 Inhibition of the biosynthesis of LTB 4 by LTA 4 hydrolase has become a potential strategy for developing anti-inflammation therapeutics. 7, 8 The epoxide hydrolase activity of LTA 4 hydrolase is determined by a 2-stage assay. The first stage is the conversion of LTA 4 to LTB 4 , and the second stage is the quantification of the LTB 4 formed. A major challenge for determining the epoxide hydrolase activity of LTA 4 hydrolase is the instability of its substrate, LTA 4 . It has been reported that LTA 4 has a half-life in a pH 7.4 phosphate buffer of < 0.5 min at 4 °C and < 0.1 min at 25 °C. 9 LTA 4 can either be hydrolyzed to LTB 4 by LTA 4 hydrolase, or it undergoes spontaneous nonenzymatic hydrolysis to 2 major diastereoisomers of LTB 4 , 6-trans LTB 4 and 6-trans-12epi LTB 4 . 10, 11 Therefore, stabilization of LTA 4 and detection specificity for LTB 4 are important factors to be considered in setting up the assay. LTB 4 has been quantified using reverse-phase (RP) high-performance liquid chromatography (HPLC) 12, 13 or enzyme-linked immunoassay (EIA). 14 The RP HPLC method is very specific with micromolar to submicromolar detection sensitivity, but because samples are subjected to solid-phase extraction and RP HPLC analysis, the HPLC procedure is labor intensive, and the throughput is considered low for drug development. The commercial LTB 4 EIA kits have been used as an alternative method for quantifying LTB 4 concentration. The commercial LTB 4 EIA kits are more sensitive with subnanomolar detection sensitivity for LTB 4 , but assay specificity varied among companies. The cross-reactivity for 2 major nonenzymatic hydrolysis products of LTA 4 , 6-trans LTB 4 and 6-trans-12epi LTB 4 for commercial LTB 4 EIA, is in the range of 0.1% to 25% and 0.03% to 5.5%, respectively. In addition, commercial LTB 4 EIA kits are in a 96-well format. No commercial 384-well LTB 4 EIA kits are available at present time. Based on our experience using the 96-well LTB 4 EIA kits, we found that the 96well format limits the throughput to 5 dose-response curves per plate, whereas the more efficient 384-well format can analyze 22 curves per plate and increase the throughput 4-fold under the present assay conditions. Therefore, there is a need to establish a 384-well LTB 4 assay to improve the overall efficiency of the LTA 4 hydrolase assay for determining compound potency.
Our attempts to develop a 384-well LTB 4 EIA using commercial reagents were unsuccessful (Beverly King, personal communication, 2006), possibly due to the difficulty in coating enough antibodies in the small-area well surface to generate sufficient signal or the inadequate sensitivity of the antibodies used. To miniaturize the LTB 4 assay, we explored the possibility of using the homogeneous time-resolved fluorescence (HTRF) technology. 15 HTRF assay technology has been widely used in the field of drug discovery. Based on distance-related fluorescence resonance energy transfer (FRET) to discriminate between bound and unbound species, the HTRF assay occurs in solution phase and requires no separation step. The assay technology uses europium cryptate as the energy donor and cross-linked allophycocyanin (XL665) as the energy acceptor. The operational simplicity, wide-signal dynamic range, and the feasibility for miniaturization make HTRF the technology of choice for designing an efficient assay for LTB 4 . To obtain consistently high assay specificity, mouse anti-LTB 4 monoclonal antibody was developed for preparing HTRF reagent. In this article, we report the development of a novel 384-well LTB 4 HTRF assay and its application in determining compound potency (IC 50 ) and screening a selected compound library for development of small-molecule LTA 4 hydrolase inhibitors. To our knowledge, this is the first report using a 384-well format, HTRF-based assay to determine LTB 4 concentration. 
MATERIALS AND METHODS

Recombinant
Preparation of mouse anti-LTB 4 monoclonal antibody
Mouse anti-LTB 4 monoclonal antibody was developed by Berlex Biosciences with collaboration of Strategic Biosolutions. LTB 4 (BIOMOL Research Lab.) was conjugated to keyhole limpet hemacyanin (KLH) or ovalbumin (OVA). Conjugation was carried out by first activation of the carboxyl group of LTB 4 with N-ethyl-N´-(dimethylaminopropyl)-carbodiimide (EDC) and Nhydroxysuccinimide (NHS) and subsequent reaction of the active ester group with the primary amine groups of the proteins. Swiss Webster mice were immunized with LTB 4 -KLH (10 mg) on days 0, 21, 42, and 63. Sera were collected on days 35, 56, and 77. Sera from the third bleed were then tested by both direct assay and enzyme-linked immunosorbent assay (ELISA) inhibition against free LTB 4 , 6-trans LTB 4 , or 6-trans-12-epi LTB 4 on LTB 4 -OVAcoated plates at 0.1 mg/well. Mice (no. 5288 and no. 5289) with best response and selectivity were selected for preparation of hybridomas. Hydridomas were screened using both direct assay and inhibition ELISA with LTB 4 -OVA-coated plates. One hybridoma (332A4) with high titer and good selectivity was subcloned and upscaled. A total of 180 mg of anti-LTB 4 monoclonal antibody (MAB 332A4) at 4.0 mg/mL concentration was purified from the ascites at Strategic Biosolutions.
Conjugation of mouse anti-LTB 4 monoclonal antibody to europium cryptate
The anti-LTB 4 antibody (Berlex Biosciences) was first incubated with N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP) (Pierce, Rockford, IL), in a molar ratio of 8 SPDP/antibody, for 30 min at room temperature. To generate free sulfhydryl groups on the molecule, dithiothreitol (DTT) (Sigma L'isle d'abeau, France), 20 mM final concentration, was then added to the reaction mixture. The reaction was carried out for 15 min at room temperature. Reaction by-products were removed by buffer exchange on a G25 superfine gel (Amersham Biotech, Les Ulis, France). The antibody was then reacted with maleimide-activated cryptate for 24 h at +4 °C in a molar ratio of 12.5 cryptates/antibody. Antibodyeuropium cryptate conjugates were finally separated from the unreacted fluorophore on a G25 superfine gel.
Conjugation of LTB 4 to cross-linked allophycocyanin (XL665)
LTB 4 was supplied as a solution in ethanol. The solvent was evaporated under a gentle nitrogen stream. The dried LTB 4 pellet was reconstituted in dimethyl formamide (DMF). LTB 4 was then reacted with dicyclohexylcarbodiimide (DCC) and NHS (all from Sigma) in a molar ratio of 1/1/1 overnight at +4 °C. The day after, the mixture was added to the allophycocyanin (XL665) molecule. Several LTB4/XL665 molar ratios were tested to define which conjugate would perform the best in the assay. After overnight incubation at +4 °C, LTB 4 -XL665 conjugate was separated from free LTB 4 on a G25 superfine gel.
HTRF assay for LTB 4
The LTB 4 HTRF assay (final volume 20 µL) was performed in 384-well small-volume black plates (Greiner cat. #784076) at room temperature on a Biomek FX. Then, 10 µL of the diluted LTA 4 hydrolase reaction mixture was transferred to the black plate, and 5 µL of LTB 4 -XL665 conjugate (final 7.5 ng/well) and 5 µL of anti-LTB 4 monoclonal antibody-cryptate conjugate (final 0.5 ng/well) were added sequentially to start the reaction. Conjugates were diluted in 50 mM phosphate, 0.8 M KF, and 0.1% casein, pH 7.0 buffer. Positive control without LTB 4 , negative control without both LTB 4 and LTB 4 -XL665, and an LTB 4 standard curve were run in parallel in the same plate. LTB 4 standards (0.094-48 nM) were serially diluted at 1:2 dilution in a buffer containing 9 parts of 50 mM phosphate, 0.1% casein (pH 7.0 buffer), and 1 part of LTA 4 hydrolase assay buffer (50 mM HEPES, 0.5% BSA [pH 7.5], and 1% DMSO). After reagent additions, assay plates were centrifuged briefly at 2000 rpm at room temperature. Plates were covered with foil seal and incubated at room temperature for 2 h. For each well, both 620 nm and 665 nm fluorescences were simultaneously read on a RUBYStar, a dual-wavelength fluorometer (BMG Labtechnologies, Inc., Durham, NC). Results represent the addition of 20 readings/well; the integration delay was 50 µs, and the integration time was 400 µs. Signal ratios of 665 nm/620 nm were used for result calculation. Specific FRET, expressed as Delta F (%), represents [(Signal ratio of sample -Signal ratio of negative control)/(Signal ratio of negative control)] × 100%.
LTB 4 EIA assay
The 96-well LTB 4 EIA assay was performed using the Leukotriene B 4 EIA kits purchased from Cayman Chemicals Co. Assay conditions and procedures used were those provided by the manufacturer. In brief, the assay is based on the competition between LTB 4 and LTB 4 -acetylcholinesterase conjugate for rabbit LTB 4 antiserum. The antigen and antibody complex in turn binds to the mouse antirabbit monoclonal antibody attached to a 96-well plate. After removing the unbound reagents by washing, a mixture of acetylthiocholine (substrate) and Ellman's reagent was added to yield a yellow-colored product, 5-thio-2-nitrobenzoic acid. The bound antigen-antibody complex was quantified by measuring absorbance at 405 nm.
Determination of the epoxide hydrolase activity of LTA 4 hydrolase
The LTA 4 hydrolase assay was performed in 384-well plates (Greiner cat. #781280) at room temperature on a Biomek FX instrument. Assay conditions were as described in the literature with modification. 14 Final assay mixture (50 µL total volume) contains 50 mM HEPES (pH 7.5), 0.5% BSA (fatty acid free), 18 nM LTA 4 hydrolase, 150 nM LTA 4 , 1% DMSO, and test compound. LTA 4 hydrolase was incubated with test compound for 10 min. The reaction was then initiated by addition of LTA 4 substrate and proceeded for 10 min. At the end of the 10-min incubation, the 8-µL incubation mixture was taken and diluted 10-fold in 72 µL of 50 mM phosphate, 0.1% casein (pH 7.0 buffer). LTB 4 formed was quantified with the LTB 4 HTRF assay as described above.
Determination of compound potency
Eight serially diluted compound concentrations at 1 to 3.16 (half log) dilution were used in the LTA 4 hydrolase HTRF assay or EIA for IC 50 determination. Controls without test compound or with a reference compound were run parallel in the same assay plate. The IC 50 values were calculated from dose-response curves by nonlinear fit of data to the 4-parameter fit equation. At least 2 independent determinations were made for each IC 50 value.
RESULTS AND DISCUSSION
Design, specificity, and optimization of the LTB 4 HTRF assay
The LTB 4 HTRF assay is a competitive inhibition assay in which free LTB 4 competes with the LTB 4 -XL665 conjugate (energy acceptor) for the anti-LTB 4 monoclonal antibodyeuropium cryptate conjugate (energy donor), thereby inhibiting the energy transfer ( Fig. 1) . Because specificity is important for determining the epoxide hydrolase activity of LTA 4 hydrolase due to the instability of the LTA 4 substrate, studies were performed to examine the specificity of Berlex's proprietary mouse anti-LTB 4 monoclonal antibody toward LTB 4 versus 2 major nonenzymatic hydrolyzed products of LTA 4 , 6-trans LTB 4 and 6-trans-12-epi LTB 4 . Results in Figure 2 show that the affinity of the anti-LTB 4 monoclonal antibody for LTB 4 was 1-2 or 2-3 order magnitudes higher than that for 6-trans LTB 4 or 6-trans-12-epi LTB 4 , respectively. The cross-reactivity was determined to be 5.5% toward 6-trans LTB 4 and 0.19% toward 6-trans-12-epi LTB 4 . Table 1 shows a comparison of specificity of the anti-LTB 4 monoclonal antibody with that of commercial LTB 4 EIA kits using either LTB 4 antiserum (Cayman Chemicals) or anti-LTB 4 polyclonal antibody (Assay Designs, Ann Arbor, MI; Neogen, Lansing, MI; and R&D Systems, Minneapolis, MN). Of the 4 companies providing LTB 4 EIA kits, only 3 reported the specificity data for 6-trans LTB 4 and 6trans-12-epi LTB 4 . The LTB 4 HTRF assay has higher specificity for 6-trans-12-epi LTB 4 than all 4 current commercial EIA kits. The specificity for 6-trans LTB 4 of LTB 4 HTRF is higher than the Neogen EIA kits or similar to the Assay Designs EIA kits but lower than the current lot of Cayman EIA kits. The data in Table 1 indicate that the specificity of commercial EIA kits varies among companies and between lots from the same company. The variation of the specificity of commercial EIA kits using antiserum or polyclonal antibody may offer hope that a mouse monoclonal antibody with even greater selectivity than our current anti-LTB 4 monoclonal antibody may be found. However, based on our present results, we concluded that the low cross-reactivity (close to or less than 5%) of the anti-LTB 4 monoclonal antibody toward the 2 LTA 4 hydrolytic products made it a suitable reagent for developing the LTB 4 HTRF assay. Another advantage of using monoclonal antibody produced from a table hybridoma cell line is the ability to maintain the consistency of specificity between different lots of this reagent.
The LTB 4 HTRF assay was established by optimizing the reagent concentrations, buffer composition, and incubation time. The optimal XL665 conjugate was found to be the one with an initial coupling ratio of 5 LTB 4 /XL665. Figure 3 shows 
Effect of protein blocking agent on the sensitivity of the LTB 4 HTRF assay
During optimization for the LTB 4 HTRF assay, it was observed that different protein blocking agents affect the detection sensitivity of the LTB 4 HTRF assay to various extents. Among the 4 protein blocking agents tested (at 0.1%)-that is, BSA, casein, acetylated BSA, and gelatin-BSA decreases the detection sensitivity for LTB 4 to the greatest extent, whereas casein does so to the least extent ( Fig. 4) . Based on the results, casein at 0.1% was used as a blocking agent in the LTB 4 HTRF assay.
Assay miniaturization and the concentration-inhibition curve of LTB 4
The LTB 4 HTRF assay was developed initially in a 96-well format with a total assay volume of 100 µL. When the assay was performed under optimized assay conditions in the presence of increasing concentrations of LTB 4 from 0.093 to 23.8 nM, an IC 50 value of 1.3 nM was obtained (Fig. 5) . The optimal detection range for LTB 4 in the 96-well assay format lies within the 20% to 80% inhibition range of about 0.4 to 6 nM LTB 4 . The LTB 4 HTRF assay performed similarly when it was miniaturized from the 96well (100 µL) to the 384-well format (20 µL), with an IC 50 value of 2.1 nM obtained for the 384-well assay (Fig. 5) . The feasibility of the LTB 4 HTRF assay to be miniaturized to the 384-well format is one major advantage over the EIA-based LTB 4 assay. The 384-well HTRF assay increases the assay efficiency by reducing the number of assay plates and assay time and by eliminating the plate-washing steps as compared to the 96-well EIA. The detection sensitivity of the LTB 4 HTRF assay, as represented by the LTB 4 concentration to achieve 20% inhibition, is either similar to or about 10-fold less than that of the commercial LTB 4 EIA kits. Based on information available from the Web site of the 4 companies specified in Table 1 , the detection sensitivity for LTB 4 by EIA varies among companies, with the most sensitive at 0.04 nM and the least sensitive at 0.3 nM. The subnanomolar detection limit of the LTB 4 HTRF assay provides more than adequate sensitivity for measuring the LTA 4 hydrolase activity under the present experimental conditions. The LTA 4 hydrolase reaction mixtures under the present conditions have to be diluted 10-fold prior to running the LTB 4 HTRF assay.
Establish a 384-well LTA 4 hydrolase HTRF assay for determining inhibitor potency of the LTA 4 hydrolase
A 384-well LTA 4 hydrolase HTRF assay was established by coupling the LTB 4 HTRF assay with the LTA 4 hydrolase reaction.
The LTA 4 hydrolase HTRF assay established in this report is mainly for determining the potency (IC 50 ) of LTA 4 hydrolase inhibitors and screening selected compound libraries for lead optimization. The LTA 4 hydrolase reaction conditions used in the present report were similar to those described in the literature with modifications. 14 The major concern is to stabilize the LTA 4 substrate and to minimize the nonenzymatic hydrolysis of the substrate during the course of the reaction. Because BSA prolongs the LTA 4 aqueous half-life drastically in a concentrationdependent manner, 9 BSA at 0.5% concentration was included in the assay buffer. To minimize the nonenzymatic hydrolysis of LTA 4 , the assay was performed under conditions to convert about 60% of LTA 4 to LTB 4 . This was accomplished by allowing the reaction to proceed for 10 min at a substrate concentration below K m at 0.15 µM. The present assay did not measure the hydrolase initial rate; however, because the compound potency was expressed as IC 50 and not K i , these assay conditions were considered adequate. Compound potency can be compared and ranked as long as IC 50 determinations are performed under the same assay conditions. Detection sensitivity of the LTB 4 HTRF assay has been shown to be affected significantly by the presence of BSA (Fig. 4) . BSA was carried over from the LTA 4 hydrolase reaction mixture and presented at a final concentration of 0.05% in all diluted samples ready for the LTB 4 HTRF assay. It is therefore important to modify the composition of the dilution buffer for the LTB 4 standard (50 mM phosphate, 0.1% casein, pH 7.0) so it resembles that of the diluted reaction samples for accurate determination of LTB 4 . The modified LTB 4 dilution buffer was prepared by mixing the reaction buffer (50 mM HEPES [pH 7.5], 0.5% BSA, and 1% DMSO) and the original dilution buffer (50 mM phosphate, 0.1% casein, pH 7.0) at a 1:9 ratio (v/v). By using the modified LTB 4 dilution buffer, the LTB 4 inhibition curve was shifted to a higher concentration range, and the IC 50 for LTB 4 increased by about 60% (data not shown). An LTB 4 IC 50 value of about 3 to 5 nM was routinely obtained with the modified dilution buffer.
Effect of HTRF incubation time on IC 50 determination of LTB 4
It has been determined previously that a 2-h incubation is optimal for the FRET signal (% delta F) for the LTB 4 HTRF assay. Studies were conducted to further examine the effect of incubation time on the inhibition curve and the IC 50 value of LTB 4 (LTB 4 standard curve). In this study, the LTB 4 HTRF assay was carried out for a 1-h, 2-h, or overnight (18-h) incubation period at room temperature. Although the signal at 620 nm was essentially unchanged, the signal at 665 nm, especially at a lower LTB 4 concentration, increased by prolonging the incubation time. The ratio of 665/620 and, ultimately, the % delta F therefore was higher at longer incubation times. The IC 50 value of LTB 4 after a 1-h or 2-h incubation was similar at about 5 nM but increased 2-fold to about 10 nM after an 18-h incubation. One possible explanation is the instability of LTB 4 after overnight incubation. Results confirmed that the 2-h HTRF incubation time is optimal for determining the IC 50 of LTB 4 .
Effect of DMSO on LTB 4 HTRF and LTA 4 hydrolase assays
The LTA 4 hydrolase HTRF assay is potentially a useful assay to identify and determine the potency of small-molecule inhibitors for LTA 4 hydrolase. Because most small-molecule compounds are dissolved in DMSO, the effect of DMSO concentration increasing from 0.03% to 2.0% on the LTA 4 hydrolase assay and the LTB 4 HTRF assay was examined. For the LTA 4 hydrolase assay, the hydrolase reaction was carried out in the absence or presence of increasing DMSO concentration from 0.03% to 2%. For the LTB 4 HTRF assay, LTB 4 standard at 3 nM was assayed in the absence or presence of increasing DMSO concentration from 0.03% to 2%. Positive control (without LTB 4 ) and negative control (without both LTB 4 and LTB 4 -XL665 conjugate) were run for each DMSO concentration in the LTB 4 HTRF assay. The effect of DMSO was evaluated by determining the percentage of the ratio of % delta F in the presence of DMSO versus that in the absence of DMSO. Both assays were found to have rather high tolerance toward DMSO. Increasing the DMSO concentration from 0.03% to 2% has no significant effect on the % delta F in both assays.
Quality of LTB 4 HTRF and LTA 4 hydrolase HTRF assays
To assess the quality of these 2 assays, Z´ factor and signalto-background (S/B) ratio were determined. Z´ factor is a parameter defined to reflect both the assay signal dynamic range and data variation and is widely used to assess assay quality for compound screening. 16 The Z´ factor for the LTB 4 HTRF assay was determined under the experimental conditions of competitive inhibition by LTB 4 . Positive signal (maximal activity) was defined as 665/620 ratio in the absence of LTB 4 , and the negative control (minimal background activity) was defined as 665/620 ratio in the absence of both LTB 4 and LTB 4 -XL665. For the LTA 4 hydrolase HTRF assay, the positive control (maximal activity) was defined as [LTB 4 ] formed by the enzyme in the absence of compound, and the negative control (minimal background activity) was defined as [LTB 4 ] formed in the presence of 1 µM SC-57461A, a potent known inhibitor of LTA 4 hydrolase. 17 Table 2 summarizes the Z´ factor and S/B ratio for both assays. The Z´ factor for LTB 4 HTRF and LTA 4 hydrolase HTRF is 0.89 and 0.56, respectively, in the range between 0.5 and 1, indicating both are reliable assays. 16 The somewhat lower Z´ factor for the LTA 4 hydrolase HTRF assay is due to the very low but more variable negative control values. These 2 assays also have wide dynamic range, as evidenced by the rather high S/B ratio obtained. About a 14-or 26-fold increase in signal over background was observed for the LTA 4 hydrolase HTRF assay and LTB 4 HTRF assay, respectively.
Validation of the LTA 4 hydrolase HTRF assay for determining compound potency: Comparison of LTB 4 HTRF with LTB 4 EIA
To examine if the LTA 4 hydrolase HTRF assay is suitable for determining compound potency, IC 50 values of 16 compounds were determined using the LTA 4 hydrolase HTRF assay (384well) and LTA 4 hydrolase EIA (96-well). The LTA 4 hydrolase reaction was performed under identical conditions for these 2 assays. The LTB 4 formed by the enzyme was subsequently quantified using either LTB 4 HTRF or the LTB 4 EIA Kit (Cayman). The 16 compounds include 2 known inhibitors, SC-57461A 17 and compound 4d, 14 and 14 inhibitors synthesized by Berlex. IC 50 values obtained from these 2 assays were then compared and correlated. A correlation plot for IC 50 values obtained from these 2 assays is shown in Figure 6 . Out of 16 compounds tested, 12 have IC 50 values from these 2 assays agree within about 2-fold. IC 50 values of the remaining 4 compounds agree within 3-to 6-fold. A correlation coefficient of 0.84 obtained indicated a good correlation between LTB 4 HTRF and LTB 4 EIA because the hydrolase reaction was performed under identical condition for both assays. Results demonstrated that the LTA 4 hydrolase HTRF assay is a suitable assay for determining potency of inhibitors of LTA 4 hydrolase.
Effect of LTA 4 hydrolase inhibitory compounds on the LTB 4 HTRF assay
Because test compounds at the final 1/20th of the assay concentrations were present in the LTB 4 HTRF assay under the present assay conditions, studies were performed to determine the effect of compound concentration on the LTB 4 HTRF assay. The effect of 11 compounds from 3 different structure templates at 50 nM, 158 nM, and 500 nM, corresponding to 1 µM, 3 µM, and 10 µM in the LTA 4 hydrolase reaction, was tested in this study. The LTB 4 HTRF assay was carried out in the absence of LTB 4 to measure the full capacity of fluorescence energy transfer. Results were presented as a percentage of the 665/620 signal ratio in the presence of compound compared to that of control without compounds. As shown in Figure 7 , 10 of 11 compounds when tested at 50-nM to 500-nM concentrations had little effect on the LTB 4 HTRF assay, with signal ratios at 80% to 100% of the control value. However, 1 particular compound decreased the signal ratio from about 80% to 65% or 40% of the control value upon increasing the concentration from 50 nM to 158 nM or 500 nM, respectively. Therefore, the effect is compound structure and compound concentration dependent. The highest compound concentration tested in our routine LTA 4 hydrolase assay usually fixed at either 1 µM or 3 µM depending on the compound structure, and these concentrations translate into either 50 nM or 158 nM, respectively, in the final LTB 4 HTRF assay. Therefore, based on the data in Figure 7 , the effect of compound concentration on assay performance is anticipated to be relatively small during routine use. However, when higher compound concentrations (≥10 µM) are tested, a dilution factor greater than 10 should be used for diluting the enzyme/compound reaction mixtures prior to the HTRF assay to avoid a possible decrease in the HTRF signal by the compounds. If present, such a reduction in HTRF signal would lead to underestimation of the inhibitory effect of the compounds.
Application of the LTA 4 hydrolase HTRF assay in determining inhibitor potency and screening selected compound libraries
To further test the utility of the 384-well LTA 4 hydrolase HTRF assay in measuring inhibitor potency, IC 50 values of 5 known small-molecule inhibitors of LTA 4 hydrolase were determined. These include Bestatin, a well-characterized inhibitor of LTA 4 hydrolase, 18, 19 and 4 other inhibitors from Pharmacia Corporation (Skokie, IL). 7 Results in Table 3 show that the IC 50 values of the 5 inhibitors obtained ranged from low nanomolar to micromolar concentrations and within 1-to 5-fold of the published values. 7, 19 Except for SC-57461A, the potency rank order for the remaining 4 compounds was consistent with that in the literature. 7, 19 Figure 8 shows a representative concentration-inhibition curve of SC-57461A. An average IC 50 value of 13.5 ± 6.1 nM (n = 158) obtained for SC-57461A in the present studies was higher than the reported value of 2.5 ± 0.095 (n = 4). 17 Because the IC 50 value is assay conditions dependent, the difference in IC 50 of SC-57461A observed likely resulted from the difference in the LTA 4 hydrolase assay conditions.
In addition, the 384-well LTA 4 hydrolase HTRF assay showed utility in screening compound libraries. This assay has been used at Berlex to screen focus libraries and combinatory compound libraries for lead optimization. Figure 9 shows the FIG. 6. Correlation of compound IC 50 values obtained from the leukotriene A 4 (LTA 4 ) hydrolase homogeneous time-resolved fluorescence (HTRF) assay versus those from the LTA 4 hydrolase enzymelinked immunoassay (EIA). LTA 4 hydrolase IC 50 values of 16 compounds were determined using the 384-well HTRF-based and the 96-well EIA-based LTA 4 hydrolase. The epoxide hydrolase activity of LTA 4 hydrolase was determined under identical reaction conditions for both the HTRF-based and EIA-based assays. The LTB 4 product concentrations in the reaction mixtures were then determined using either the LTB 4 HTRF assay or the LTB 4 EIA kits purchased from Cayman Chemicals. Assay conditions and procedures were as described in Materials and Methods. IC 50 values were the mean of at least 2 independent determinations.
FIG. 7. Effect of test compounds on the leukotriene B 4 (LTB 4 )
homogeneous time-resolved fluorescence (HTRF) assay. The LTB 4 HTRF assay was performed without LTB 4 and in the absence or presence of test compounds at 50, 158, or 500 nM concentrations. Results were presented as the percentage of the 665/620 ratio obtained in the presence of compound compared to that in the absence of compound (control). Results are the mean ± SD of 4 determinations. results of screening a combinatory compound library consisting of 248 compounds synthesized for lead optimization. Compounds were tested at a single concentration of 0.1 µM in duplicate. Control without compound or with a standard compound was run in the same plate. Results were expressed as percent inhibition compared to the control without compound. Using greater than 50% inhibition as the cutoff, 20 combinatory compounds were identified as hits from this library. By using the 384-well HTRF assay, we screened 248 compounds at 0.1 µM in duplicate in two 384-well assay plates. By way of comparison, one would need 6 to 7 of the 96-well EIA plates to screen the same number of compounds in duplicate. The 384-well LTA 4 hydrolase HTRF assay has been used successfully at Berlex to establish compound structure-activity relationships (SARs) for lead optimization and development of potent LTA 4 hydrolase inhibitors.
CONCLUSION
A novel 384-well HTRF assay for quantifying LTB 4 has been developed to facilitate the identification and optimization of LTA 4 hydrolase inhibitors. The LTB 4 HTRF assay established is an efficient, selective, and robust assay with a Z´ factor of 0.89, sub-nanomolar detection sensitivity, a high signal-to-background ratio of 26, and high tolerance to the solvent DMSO (> 2%).
A majority of the compounds tested in the present studies under the concentrations used (up to 500 nM in the LTB 4 HTRF assay) have no significant effect on the LTB 4 HTRF assay. The LTB 4 HTRF assay was validated by results showing that the IC 50 values of 16 inhibitors determined using the HTRF method were comparable to those obtained using the commercial LTB 4 EIA kits. The studies presented here demonstrate the utility of the HTRF-based LTA 4 hydrolase assay both for determining compound potency (IC 50 ) and for compound library screening. The HTRF-based LTA 4 hydrolase assay has been successfully used at Berlex to establish compound SAR for lead optimization and inhibitor development, which will be the subjects of future publications. The IC 50 value represents the mean ± SD of 158 independent determinations for SC-57461A and at least 2 independent determinations for the other 4 compounds. Each determination was performed in duplicate wells. LTA 4 = leukotriene A 4 ; HTRF = homogeneous time-resolved fluorescence.
FIG. 8. Representative concentration-inhibition curve of SC-57461A.
A representative concentration-inhibition curve of SC-57461A was determined using the 384-well leukotriene A 4 (LTA 4 ) hydrolase homogeneous time-resolved fluorescence (HTRF) assay. Results are the mean ± SD of 2 determinations. IC 50 value was calculated to be 11 nM from the curve. 
